ADC revolution is marching on!
🧵 At #AACR26 plenary, @raffcolo at @ZymeworksInc discussed new breakthroughs in RAS inhibition 👇

💊 Pan-RASi RMC-6236 shows real benefit (38% ORR in NSCLC, 25% in PDAC) but skin/GI toxicity & dose reductions remain a major problem
💡 Solution? RASi-ADCs — same target, sustained tumor delivery, far less systemic exposure
🔬 170+ novel payloads screened → DAR=8 ADCs show strong efficacy at 1mg/kg, good PK, bystander killing, and no skin or GI tox in NHPs 🐒
🎯 Key data: RASi-ADCs suppress RAS in tumor — but spare liver, skin & colon. RMC-6236 doesn’t.

The future of RAS therapy may be in the syringe, rather than the pill 💉
@AACR @oncodaily @AACR @LUNGevity